Clinical trials: Pseudomonas Infections
Cystic Fibrosis, Pseudomonas Aeruginosa
Volatile Organic Compounds in Cystic Fibrosis
This experiment is designed to test the effectiveness of a new electronic nose device, which allows a non-invasive breath test for markers of lower respiratory tract infection, which may predict the probability of bacterial…
- Trial name
- VOCCF (NCT01379040)
- Testing
- Cystic Fibrosis patients
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Landon Pediatric Foundation
Pseudomonas Infections
Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin
This study is designed to provide data about the pharmacokinetics (PK), safety and tolerability of two continuous treatment regimes of tobramycin nebulized solution delivered via a 'soft mist' nebulizer in Cystic Fibrosis (CF)…
- Trial name
- NCT00634192
- Testing
- tobramycin
- Where
- 8 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Novartis
Urinary Tract Infections
Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens
Researchers want to find out if a drug called Cipro® XR (ciprofloxacin extended-release) can help people with a complicated urinary tract infection caused by a kind of bacteria called Pseudomonas aeruginosa.
- Trial name
- NCT00481689
- Testing
- Cipro XR (Ciprofloxacin, BAYQ3939)
- Where
- 35 sites in United States
- Volunteers
- 500 people
- Sponsor
- Bayer
Brain and Central Nervous System Tumors
IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma
RATIONALE: IL-4(38-37)-PE38KDEL immunotoxin may locate tumor cells and kill them without harming normal cells. This may be an effective treatment for recurrent malignant astrocytoma.
- Trial name
- NCT00003842
- Testing
- interleukin-4 PE38KDEL cytotoxin, isolated perfusion, surgical procedure
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Barrett Cancer Center
Severe Infection
CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients
Ceftazidime/avibactam (CZA) is an essential treatment option for managing infections caused by multidrug-resistant (MDR) gram-negative (G-) bacteria, including Klebsiella pneumoniae OXA-48 and carbapenem-resistant Pseudomonas…
- Trial name
- ZAVICONT (NCT06811727)
- Testing
- Continuos ceftazidime/avibactam infusion, Intermitent dosing as per SMPC
- Where
- Croatia
- Volunteers
- 140 people
- Sponsor
- Ivan Šitum, MD
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa
Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
A phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 administered in subjects with non-cystic fibrosis bronchiectasis and chronic…
- Conditions
- Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
- Trial name
- Tailwind (NCT05616221)
- Testing
- AP-PA02
- Where
- 23 sites in United States
- Volunteers
- 48 people
- Sponsor
- Armata Pharmaceuticals, Inc.
Pseudomonas Aeruginosa, Cystic Fibrosis
Open Label Extension to Bridging Study CTBM100C2303
This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who had completed their study participation in CTBM100C2303 (all visits) and who were proven infected with Pseudomonas…
- Trial name
- NCT00982930
- Testing
- Tobramycin inhalation powder
- Where
- 2 sites in Estonia, Russia
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Pneumonia, Ventilator Associated Pneumonia
Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa
The objectives of this open study are to assess the safety, tolerability, pharmacokinetics and clinical outcome of patients who have HAP caused by Pseudomonas aeruginosa serotype O11 after three separate administrations of…
- Trial name
- NCT00851435
- Testing
- KBPA-101
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- Kenta Biotech Ltd
Cystic Fibrosis
Evaluation of Ciprofloxacin for Inhalation to Cystic Fibrosis Patients With P. Aeruginosa
This is a Phase 1/2a, multicenter study, designed to evaluate the pharmacokinetics, safety, and tolerability of once daily administration of 150 mg of Ciprofloxacin for Inhalation (CFI) in patients with Cystic Fibrosis who have a…
- Trial name
- NCT01090908
- Testing
- Antibiotic
- Sponsor
- Aradigm Corporation
Healthy
Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers
The objective is to confirm the optimal dose of IC43 in regard to immunogenicity, safety and tolerability.
- Trial name
- NCT00778388
- Testing
- IC43
- Where
- 3 sites in Austria, Germany
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Cystic Fibrosis, Pseudomonas Aeruginosa
A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies
This is a pilot study of inhaled antibiotic regimens is a pilot study examining clinical and laboratory endpoints of patients on inhaled antibiotic treatments.
- Trial name
- NCT01319253
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Indiana University
Cystic Fibrosis, Pneumonia
Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
This study will determine the concentrations of the antibiotic meropenem when administered as a 3 hour prolonged infusion in children with cystic fibrosis who are hospitalized with an acute pulmonary exacerbation.
- Conditions
- Cystic Fibrosis, Pneumonia, Pseudomonas Aeruginosa Infection
- Trial name
- NCT01429259
- Testing
- meropenem
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Joseph Kuti
COPD, Respiratory Tract Infections
Targeted AntiBiotics for Chronic Pulmonary Diseases
This is a prospective, randomized multi-center trial investigating the impact of lower airway infection with P. aeruginosa in COPD patients. The aim of the study is to evaluate if targeted antibiotic therapy against P.
- Conditions
- COPD, Respiratory Tract Infections, Pseudomonas Aeruginosa, Bronchiectasis
- Trial name
- Target-ABC (NCT03262142)
- Testing
- Piperacillin/tazobactam, Ciprofloxacin
- Where
- Denmark
- Volunteers
- 51 people
- Sponsor
- Chronic Obstructive Pulmonary Disease Trial Network, Denmark
MDRPA
Clinical Study on the Treatment of Lower Respiratory Tract Infection With Pseudomonas Aeruginosa by Ceftazidime and Avibatam
Multidrug-resistant Gram-negative bacteria (MDR-GNB) is emerging globally as a pathogen of concern in healthcare-associated infections (HAIs), and a threat to public health.There has been an alarming rise in the prevalence of…
- Trial name
- NCT06992102
- Where
- China
- Volunteers
- 500 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Healthy Participants, Non-cystic Fibrosis Bronchiectasis
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa
This is a Phase 1a/1b study to test the safety, tolerability, microbiological response, and pharmacokinetics of inhaled Rev-56 compared to placebo in adult healthy participants and non-cystic fibrosis bronchiectasis (NCFB)…
- Trial name
- NCT07709494
- Testing
- Rev-56 for Inhalation
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Revagenix, Inc.
Non-Cystic Fibrosis Bronchiectasis
Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)
A Phase 1/2a, Multi-Centre, Randomised, Open-label study to assess the safety, tolerability, PK, and efficacy of RESP30X in Adult NCFB participants with confirmed high-titre respiratory PPMs.
- Trial name
- NOPA (NCT06663176)
- Testing
- RESP302, RESP303
- Where
- Ukraine
- Volunteers
- 60 people
- Sponsor
- Thirty Respiratory Limited
Cystic Fibrosis
Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis
This study assessed time to recurrence of infection with Pseudomonas aeruginosa following treatment of the initial infection with tobramycin nebuliser solution.
- Trial name
- ELITE (NCT00391976)
- Testing
- Tobramycin solution for inhalation 300 mg
- Volunteers
- 123 people
- Sponsor
- Novartis
Pseudomonas Aeruginosa, COVID-19
Pseudomonas Aeruginosa Infections Among COVID-19 Patients in Intensive Care Units at CHRU of Nancy (Pyo-COVID-3)
P. aeruginosa is an opportunistic bacterium known to be responsible for numerous healthcare-associated infections, particularly in intensive care units (ICU).
- Trial name
- Pyo-COVID-3 (NCT06141837)
- Testing
- Observation
- Volunteers
- 51 people
- Sponsor
- Central Hospital, Nancy, France
Cystic Fibrosis
Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis
Cystic Fibrosis patients attending with infective exacerbations will be enrolled into the study. The trial is a double blinded, randomised trial with patients randomised to 10,14 or 21 days of antibiotic therapy, comprising of…
- Trial name
- NCT01044719
- Testing
- Ceftazidime, Tobramycin, Meropenem
- Where
- United Kingdom
- Volunteers
- 240 people
- Sponsor
- Imperial College London
Ventilator Associated Bacterial Pneumonia, Pseudomonas Aeruginosa Infection
A Double-Blind, Placebo-Controlled Study of Nebulized Bacteriophages in Patients With Ventilator-Associated Pneumonia Due to Pseudomonas Aeruginosa
Ventilator-associated pneumonia (VAP) complicates the hospital course of up to 40% of mechanically ventilated patients and is associated with mortality rates approaching 30%, despite appropriate antibiotic therapy (ATB).
- Trial name
- PYOPHANEB (NCT07804082)
- Testing
- Bacteriophages GMP
- Where
- 16 sites in France
- Volunteers
- 184 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris